



# Exploration of potential therapeutic targets for stroke based on the GEO database

Li-Zhong Ma<sup>1#</sup>, Ling-Wan Dong<sup>2#</sup>, Jing Zhu<sup>1</sup>, Jian-Song Yu<sup>1</sup>, Qi-Long Deng<sup>1</sup>

<sup>1</sup>Rehabilitation Medical Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China; <sup>2</sup>Pharmacy Center, Linhai Hospital of Traditional Chinese Medicine, Linhai, China

**Contributions:** (I) Conception and design: LZ Ma, LW Dong; (II) Administrative support: J Zhu; (III) Provision of study materials or patients: LZ Ma, JS Yu; (IV) Collection and assembly of data: LW Dong; (V) Data analysis and interpretation: QL Deng; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

<sup>#</sup>These authors contributed equally to this work.

**Correspondence to:** Qi-Long Deng. Rehabilitation Medical Center, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, 150 Ximen Street, Linhai 317000, China. Email: thesunandyou@163.com.

**Background:** This study aimed to analyze non-coding RNA sequencing results, screen differentially expressed long non-coding RNAs (lncRNAs), and predict lncRNA target genes. It further clarifies the potential functions of lncRNAs, thus exploring potential biomarkers and therapeutic targets for stroke.

**Methods:** lncRNA sequencing data of blood samples from stroke patients and healthy subjects (*GSE102541* and *GSE140275*) were downloaded from the Gene Expression Omnibus (GEO) database. This study used R software and related R packages to conduct a batch correction and differential analysis of sequencing results. It also screened differentially expressed lncRNAs and visualized the correlations between significantly different lncRNAs. Target genes of differential lncRNAs were predicted by the StarBase database. Gene ontology (GO) functional enrichment analysis of related target genes was performed using the DAVID database. Principal component analysis was performed based on the expression levels of lncRNAs with the most significant differences in stroke blood samples.

**Results:** A total of 239 differentially expressed lncRNAs were screened out in this study, of which 146 were upregulated and 93 were downregulated. According to  $|\log_2FC|$  values from highest to lowest, the top 10 lncRNAs with the most significant differences were selected. The upregulated lncRNAs were *LINC02334*, *TARID*, *MRGPRF-AS1*, *CAI2*, *LINC00189*, *TUG1*, and *RNF5P1*. The downregulated lncRNAs included *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3*. *TARID* was strongly correlated with *MRGPRF-AS1*. Meanwhile, *LINC02334* was strongly correlated with *TUG1*. *CAI2*, *LINC00189*, and *RNF5P1* were at the core of the correlation network and may therefore be the critical lncRNAs in stroke pathogenesis. GO functional enrichment results indicated that genes were significantly enriched in muscle contraction, RNA polymerase II promoter transcription regulation, muscle structure composition, focal adhesion, endothelial cell chemotaxis, actin, actin cytoskeleton, actin filament binding, blood lipid regulation, smooth muscle contraction regulation, skeletal muscle cell differentiation, and other functions. Principal component analysis showed that the 10 lncRNAs with significant differences could significantly distinguish stroke blood samples from healthy control blood samples, and could characterize the essential characteristics of stroke.

**Conclusions:** *LINC02334*, *TARID*, *MRGPRF-AS1*, *CAI2*, *LINC00189*, *TUG1*, *RNF5P1*, *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3* play an essential role in the pathogenesis of stroke, and may be potential therapeutic targets.

**Keywords:** Long non-coding RNA (lncRNA); biological markers; therapeutic targets

Submitted Nov 14, 2021. Accepted for publication Dec 02, 2021.

doi: 10.21037/atm-21-5815

**View this article at:** <https://dx.doi.org/10.21037/atm-21-5815>

## Introduction

Stroke threatens the life and health of patients and causes long-term disability, which seriously reduces patients' quality of life. In recent years, stroke has risen from the second leading cause of death to China's leading cause of death. Ischemic stroke accounts for 70–85% of all strokes. At present, the only standard treatment for acute ischemic stroke is intravenous thrombolysis and mechanical thrombectomy with intravenous tissue plasminogen activator within 3 to 4.5 hours after the onset of symptoms. However, the narrow therapeutic time window of intravenous tissue plasminogen activator thrombolysis has prompted researchers to seek new therapeutic strategies and drugs. In recent years, due to the wide application of high-throughput sequencing technology, some substantial progress has been made in the study of the pathological mechanism of stroke. Studies have jointly analyzed mRNA and miRNA sequencing data sets, identified 6 core mRNAs and 2 regulated miRNAs in the pathogenesis of stroke, and explained the impact of systemic lupus erythematosus and atypical infections on stroke (1). Therefore, further studying the pathophysiological mechanisms of stroke development and recovery may provide a new and more effective approach to improving stroke patients' prognoses. In general, non-coding RNAs, including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are widely expressed in the human central nervous system and are related to a variety of nervous system diseases (2). Current research shows that lncRNAs play an important role in regulating gene expression (3) and participate in many vital biological processes, such as differentiation, organogenesis, apoptosis, genomic imprinting, regulation of mRNA splicing, and translation control (4). In recent years, many researchers have shown great interest in exploring the relationship between the lncRNA spectrum and stroke, and confirmed the key pathogenic role of lncRNA (5–7). A clinical study confirmed that lncRNA SNHG15 can be used as a diagnostic marker for ischemic stroke (5). Wang *et al.* (6) showed that H19 is associated with a good prognosis in stroke patients and may have a protective effect on brain tissue and nerves. Moskowitz *et al.* (7) showed that lncRNA is involved in neuronal cell regulation in stroke patients. Therefore, the purpose of this study is to jointly analyze the sequencing results of 2 groups of non-coding RNAs, screen the differentially expressed lncRNAs, and predict the target genes of the lncRNAs. This study aims to clarify the potential functions of lncRNAs and explore the potential biomarkers and therapeutic targets of stroke.

We present the following article in accordance with the MDAR checklist (available at <https://dx.doi.org/10.21037/atm-21-5815>).

## Methods

### *Data download*

The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). In this study, lncRNA sequencing data (*GSE102541*, *GSE140275*) of blood samples from stroke patients and healthy subjects were downloaded from the Gene Expression Omnibus (GEO) database. A total of 15 samples of lncRNA sequencing data were downloaded in this study, including 9 samples of stroke patients and 6 samples of healthy subjects. Among the 9 stroke patients, 6 cases were ischemic stroke and 3 cases were hemorrhagic stroke. A batch correction was performed on the 2 data groups to remove the impact of the experimental environment or experimental conditions on lncRNA sequencing results. The 2 data groups were normalized through standard correction and logarithmic operation and combined into a data matrix. The data matrix was the expression amount of lncRNAs in each sample. Since the lncRNA sequencing data in this study was open source, it did not need to be reviewed by the hospital ethics committee.

### *Difference analysis*


The lncRNA sequencing (lncRNA-seq) data sets was analyzed by R software (V3.5.1) and the R package edgeR. Fold change (FC) = lncRNA expression in stroke samples/lncRNA expression in healthy control samples. The difference multiple was expressed in the form of  $\log_2FC$ , and a *t*-test was used. LncRNAs with significant differences were screened based on  $|\log_2FC| > 1$  and false discovery rate (FDR)  $< 0.05$ .

### *Correlation analysis*

R software and the R package corrplot were used to calculate the correlations between significantly different lncRNAs. The R package cyclize was used for visualization. Correlations between lncRNAs were tested by the Pearson test.

### *Target gene prediction and enrichment analysis*

This study used the StarBase database (<http://starbase.sysu.edu.cn/>). Target genes were predicted for differential



**Figure 1** Differential expression of lncRNAs in blood samples from stroke patients and 6 healthy controls. Type C represents a healthy control blood sample, and type S represents a stroke blood sample. Red represents  $\log_2FC < 0$ , indicating that lncRNA expression is upregulated, while blue represents  $\log_2FC > 0$ , indicating that lncRNA expression is downregulated.

lncRNAs. Gene ontology (GO) functional enrichment analysis was carried out for related target genes. GO functional enrichment analysis was performed using DAVID data, and  $FDR < 0.05$  was used as the screening condition. The results of enrichment analysis were visualized by the R package ggplot.

### Principal component analysis

Principal component analysis was performed based on the lncRNAs with the most significant expression in stroke blood samples. Through the dimensionality reduction of the data matrix, this study explored the differentiation of the most significant lncRNAs between stroke and healthy control samples and the characterization performance of the essential characteristics of stroke samples.

### Statistical analysis


The data were statistically analyzed using R software and

related R packages.  $P < 0.05$  was considered statistically significant.

## Results

### Differentially expressed lncRNAs

The research aimed to explore the correlation between lncRNA and stroke, so it focused on the screening of differentially expressed lncRNA in blood samples of stroke patients. A total of 239 differentially expressed lncRNAs were screened in 9 stroke blood samples and 6 healthy control blood samples. The results showed that 146 genes were upregulated, while 93 genes were downregulated, as shown in *Figure 1*. According to the  $|\log_2FC|$  value, the top 10 lncRNAs with the most significant enrichment were selected. The up-regulated lncRNAs were *LINC02334*, *TARID*, *MRGPRF-AS1*, *CAI2*, *LINC00189*, *TUG1*, and *RNF5P1*, respectively. The top downregulated lncRNAs were *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3*,



**Figure 2** LncRNAs with the most significant differences between stroke blood samples and healthy control blood samples. The abscissa is log<sub>2</sub>FC, and the ordinate is gene name. Yellow indicates downregulation, and blue indicates upregulation.

respectively, as shown in *Figure 2*.

### Correlation analysis

The 10 lncRNAs with the most significant differences were used for correlation analysis. There was a significant positive correlation between the downregulated genes and upregulated genes. A strong correlation was found among *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3*. Meanwhile, a strong correlation was observed between *TARID*, *MRGPRF-AS1*, *LINC02334*, and *TUG1*, as shown in *Figure 3*. Based on the correlation network diagram in *Figure 4*, *CAI2*, *LINC00189*, and *RNF5P1* were at the core of the correlation network, indicating that they might be the critical lncRNAs for the pathogenesis of stroke.

### Target gene prediction

This study was based on StarBase (<http://starbase.sysu.edu.cn/>). The target genes of differential lncRNAs were predicted, and the relationships between mRNAs and lncRNAs are shown in *Figure 5*.

### GO enrichment analysis

As shown in *Figure 6*, the results showed that the genes


related to muscle contraction, positive regulation of RNA polymerase II promoter transcription, muscle structural components, focal adhesion, and endothelial cell chemotaxis were significantly enriched. Meanwhile, genes related to actin binding, actin cytoskeleton, actin filament binding, blood lipid regulation, positive regulation of smooth muscle contraction, and skeletal muscle cell differentiation increased in expression.

### Principal component analysis


Principal component analysis showed that the 10 lncRNAs with significant differences could distinguish between stroke blood samples and healthy control blood samples. The significantly different lncRNAs identified in this study could characterize the essential characteristics of stroke, as shown in *Figure 7*.

### Discussion

Studies have shown that lncRNAs play an important role in the pathogenesis of stroke (6,8). The specific mechanisms and functions of most lncRNAs in neuroprotection and stroke diseases need to be further studied and clarified. In non-coding RNA sequencing analysis, abnormal expression of lncRNAs is closely related to the occurrence




**Figure 3** LncRNA correlation circle. Green indicates a negative correlation, and red indicates a positive correlation.



**Figure 4** LncRNA correlation network with a significant difference. Red indicates a positive correlation, and blue indicates a negative correlation.

and progression of stroke. Other research confirmed that lncRNAs usually play essential roles in the occurrence and progression of stroke and the recovery of stroke (8,9). At present, research on the functions and mechanisms of lncRNAs is mainly focused on animal models of stroke. However, due to the noticeable biological and genetic differences between animals and humans, the human lncRNA spectrum must be further studied. In addition, the current research on this issue only focuses on a few lncRNAs, such as *GAS5*, *MALAT1*, *SNHG1*, and *ANRIL* (6,10,11). Therefore, the functions of most lncRNAs remain unclear.

This study combined 2 groups of lncRNA sequencing results (*GSE102541* and *GSE140275*) for bioinformatics analysis. We screened 239 differentially expressed lncRNAs, of which 146 were upregulated and 93 were downregulated. The top upregulated lncRNAs with the most significant differences were *LINC02334*, *TARID*, *MRGPRF-AS1*,




**Figure 5** Prediction of lncRNA-related target genes with significant differences.

*CAI2*, *LINC00189*, *TUG1*, and *RNF5P1*. In contrast, *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3* were downregulated. Most of these lncRNAs have been proven to play an important role in the pathogenesis of stroke. Previous studies found that *RNF5P1* was highly expressed in patients with ischemic stroke while its expression was low in healthy people (12). *RNF5P1* is an independent risk factor for ischemic stroke. It has a certain diagnostic value and is a potential biomarker for ischemic stroke. Wei *et al.* measured the content of lncRNA *TUG1* in serum samples of stroke patients and healthy controls and found that *TUG1* was highly expressed in blood samples of stroke patients and was correlated with an increased risk of ischemic stroke (13). Serum lncRNA *TUG1* therefore has potential diagnostic value. Previous studies found that the expression level of lncRNA *CAI2* in patients with acute ischemic stroke was higher than that in healthy controls (14). *CAI2* was considered to correlate with the severity of acute stroke and is effective in diagnosing acute stroke. The change in *CAI2* is a potential diagnostic marker (14).


This study further explored the correlations between the

10 most significant lncRNAs. We found a strong correlation among *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3*. Meanwhile, there was a strong correlation between *TARID*, *MRGPRF-AS1*, *LINC02334*, and *TUG1*, which were at the core of the correlation network and may be the key lncRNAs for the pathogenesis of stroke. The diagnostic value of *CAI2* and *RNF5P1* in stroke has been confirmed. Zhang *et al.* (15) found that lncRNA *LINC00189* may be related to the occurrence and progression of squamous urothelial carcinoma by single-cell sequencing. Four lncRNAs, including *HCG11*, *CASC15*, *LINC00189*, and *LINC00905*, were shown to be significantly correlated with the deterioration of recurrence-free survival of cervical cancer (16). In addition, there are few related studies on other lncRNAs found in this study, and some functions have not been fully elucidated, which needs further experimental exploration.

To further explore the biological functions of lncRNAs with the most significant differences, this study predicted the target genes of lncRNAs through the StarBase database and performed GO functional enrichment analysis. The



**Figure 6** GO functional enrichment analysis of lncRNA targeted genes with significant differences. GO, Gene Ontology.



**Figure 7** Principal component analysis based on the expression of significantly different lncRNAs. Red indicates stroke blood samples, and blue indicates healthy control blood samples.

results showed that the target genes were enriched in muscle contraction, positive transcriptional regulation of RNA polymerase II promoter, muscle structural components, focal adhesion, endothelial chemotaxis, actin binding, actin cytoskeleton, actin filament binding, and blood lipid regulation. Other upregulated genes were

related to positive regulation of smooth muscle contraction and skeletal muscle cell differentiation, among others. It is worth noting that of these functional items, blood lipid regulation and endothelial cell chemotaxis are closely related to the pathological basis of stroke. At the same time, focal adhesion is related to the adhesion and migration of vascular smooth muscle cells, which may lead to the occurrence and development of stroke. GO functional enrichment further confirmed that the most significant lncRNAs that were found in this study may play a vital role in the pathogenesis of stroke and are potential therapeutic targets. Based on the results of this study, we can further explore the diagnostic efficacy of differentially expressed lncRNA and its correlation with prognosis in clinical samples, and even further explore the significance of its targeted therapy.

There are some shortcomings in this study. First, the sample size is small, and the sample size needs to be further expanded to more comprehensively screen lncRNAs with significant differences in stroke. Second, due to the limitations of this study and the lack of sample size and clinical data, it is impossible to further explore the relationship between lncRNA and the prognosis of stroke patients. The clinical relevance of the differential

lncRNA identified in this study, especially the impact on the prognosis of stroke patients, still needs to be confirmed by further clinical studies. The third is that this study lacks *in vivo* and *in vitro* experimental confirmation, as well as further exploration of the mechanism of differential lncRNA based on experiments.

This study conducted a principal component analysis based on the expression of the most significantly different lncRNAs, reduced the dimension of the data, and further explored the roles of these lncRNAs in stroke. The results showed that the 10 lncRNAs with significant differences could distinguish between stroke blood samples and healthy control blood samples. In other words, they could characterize the essential characteristics of stroke to a certain extent.

## Conclusions

In conclusion, genes including *LINC02334*, *TARID*, *MKGPRF-AS1*, *CAI2*, *LINC00189*, *TUG1*, *RNF5P1*, *AC005180.2*, *ADAMTS9-AS1*, and *AC036108.3* play an important role in the pathogenesis of stroke and may be potential therapeutic targets.

## Acknowledgments

**Funding:** This research was supported by the National Natural Science Foundation of China Youth Science Foundation Project (No. 81804185) and the Zhejiang Provincial “Thirteenth Five-Year Plan” Key Specialty Construction Project Fund of Traditional Chinese Medicine [Zhejiang Health Office Traditional Chinese Medicine (2019) No. 1].

## Footnote

**Reporting Checklist:** The authors have completed the MDAR checklist. Available at <https://dx.doi.org/10.21037/atm-21-5815>

**Conflicts of Interest:** All authors have completed the ICMJE uniform disclosure form (available at <https://dx.doi.org/10.21037/atm-21-5815>). The authors have no conflicts of interest to declare.

**Ethical Statement:** The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are

appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

**Open Access Statement:** This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Xie Q, Zhang X, Peng S, et al. Identification of novel biomarkers in ischemic stroke: a genome-wide integrated analysis. *BMC Med Genet* 2020;21:66.
2. Qureshi IA, Mattick JS, Mehler MF. Long non-coding RNAs in nervous system function and disease. *Brain Res* 2010;1338:20-35.
3. Martianov I, Ramadass A, Serra Barros A, et al. Repression of the human dihydrofolate reductase gene by a non-coding interfering transcript. *Nature* 2007;445:666-70.
4. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. *Nat Rev Genet* 2009;10:155-9.
5. Deng QW, Li S, Wang H, et al. Differential long noncoding RNA expressions in peripheral blood mononuclear cells for detection of acute ischemic stroke. *Clin Sci (Lond)* 2018;132:1597-614.
6. Wang J, Zhao H, Fan Z, et al. Long Noncoding RNA H19 Promotes Neuroinflammation in Ischemic Stroke by Driving Histone Deacetylase 1-Dependent M1 Microglial Polarization. *Stroke* 2017;48:2211-2221.
7. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. *Neuron* 2010;67:181-98. Erratum in: *Neuron* 2010;68:161.
8. Liu B, Cao W, Xue J. LncRNA ANRIL protects against oxygen and glucose deprivation (OGD)-induced injury in PC-12 cells: potential role in ischaemic stroke. *Artif Cells Nanomed Biotechnol* 2019;47:1384-95.
9. Zhang L, Luo X, Chen F, et al. LncRNA SNHG1 regulates cerebrovascular pathologies as a competing endogenous RNA through HIF-1 $\alpha$ /VEGF signaling in ischemic stroke. *J Cell Biochem* 2018;119:5460-72.
10. Guo D, Ma J, Yan L, et al. Down-Regulation of Lncrna

- MALAT1 Attenuates Neuronal Cell Death Through Suppressing Beclin1-Dependent Autophagy by Regulating Mir-30a in Cerebral Ischemic Stroke. *Cell Physiol Biochem* 2017;43:182-94.
11. Kopp F, Mendell JT. Functional Classification and Experimental Dissection of Long Noncoding RNAs. *Cell* 2018;172:393-407.
  12. Bao MH, Szeto V, Yang BB, et al. Long non-coding RNAs in ischemic stroke. *Cell Death Dis* 2018;9:281.
  13. Wei YS, Yang J, He YL, et al. A functional polymorphism in the promoter of TUG1 is associated with an increased risk of ischaemic stroke. *J Cell Mol Med* 2019;23:6173-81.
  14. Wang SW, Liu Z, Shi ZS. Non-Coding RNA in Acute Ischemic Stroke: Mechanisms, Biomarkers and Therapeutic Targets. *Cell Transplant* 2018;27:1763-77.
  15. Zhang X, Zhang M, Hou Y, et al. Single-cell analyses of transcriptional heterogeneity in squamous cell carcinoma of urinary bladder. *Oncotarget* 2016;7:66069-76.
  16. Zhang Y, Zhang X, Zhu H, et al. Identification of Potential Prognostic Long Non-Coding RNA Biomarkers for Predicting Recurrence in Patients with Cervical Cancer. *Cancer Manag Res* 2020;12:719-30.
- (English Language Editor: C. Betlzar)

**Cite this article as:** Ma LZ, Dong LW, Zhu J, Yu JS, Deng QL. Exploration of potential therapeutic targets for stroke based on the GEO database. *Ann Transl Med* 2021;9(24):1759. doi: 10.21037/atm-21-5815